Fig. 3From: The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study a hsCRP values at baseline and follow up b hsCRP percentage change after 12 weeks of treatmentBack to article page